Another Child Death in China Gene-Editing Trial Disclosed Nearly a Year Later
The Shanghai-based company waited nearly a year to disclose the boy’s death and changed the trial’s public status five days before the announcement.
A child has died following an experimental gene editing treatment in China for Duchenne muscular dystrophy. The company, HuidaGene Therapeutics, only disclosed the death nearly a year after it occurred, attributing it to complications from an immune reaction. The trial involved four boys aged 4 to 8 at Shanghai Children’s Medical Center.
- A child died after receiving an experimental gene editing treatment (HG302) in China for Duchenne muscular dystrophy.
- HuidaGene Therapeutics, the company behind the treatment, did not publicly disclose the death for nearly a year.
- The death occurred in August 2025 and was attributed to acute respiratory distress syndrome following a severe immune reaction.
- The trial enrolled four boys between the ages of 4 and 8 at Shanghai Children’s Medical Center.
Write a comment